Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA

Correction to: Cell Discovery (2015) 1, 15040; doi:10.1038/celldisc.2015.40; published online 8 December 2015

In the initial published version of this article, an error was made during the description of Materials and Methods. In the section ‘In vivo bioluminescence of tumors’, we mentioned ‘Severe combined immune deficiency NPG/Vst mice obtained from the VITALSTART’. However, the name of the company is VITALSTAR, so we want to correct it. This mistake in Materials and Methods does not affect the description of the results in the paper or the conclusions of our paper. We also deeply apologize for any inconvenience that may have been caused by our error.